Search Results
Your search for ,OUr matches 10645 pages
Showing 4251 - 4300Clinical Cancer Advances 2020: ASCO Names Advance of the Year, Issues Research Priorities for the Cancer Community
In the release of its annual report on progress against cancer, Clinical Cancer Advances 2020, ASCO recognized progress in the refinement of the surgical treatment of cancer as the Advance of the Year. In particular, the emergence of novel systemic therapies—combined in new and better ways—has...
ASCO Guideline Addresses Surveillance of Lung Cancer After Curative-Intent Therapy
ASCO has released a new guideline providing recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive, curative-intent therapy in patients with stage I to III non–small cell lung cancer or small cell lung cancer. These guideline...
Diffusion-Weighted MRI May Help Predict Treatment Response in Patients With Advanced Ovarian Cancer
A simple test using a magnetic resonance imaging (MRI) scan may be used to predict how well people with advanced epithelial ovarian cancer will respond to treatment, according to the results of a new study published by Winfield et al in Radiology. In a large clinical trial, scientists have shown a...
World Cancer Day 2020: 20th Anniversary of the Global Initiative
Today’s World Cancer Day, led by the Union for International Cancer Control (UICC), aims to mobilize urgent action from individuals, governments, and the global cancer community to close gaps in cancer risk awareness between higher and lower socioeconomic groups and the subsequent impact on their...
AMA Foundation Launches New Initiative to Address LGBTQ Health Disparities
The American Medical Association Foundation (AMAF) recently announced a new initiative to create a cadre of LGBTQ health specialists through the AMA Foundation LGBTQ Fellowship Program—a national fellowship program to promote best practices and shared outcomes, while improving the quality of LGBTQ ...
Expert Point of View: Harold J. Burstein, MD, PhD, FASCO
Commenting on Dr. DeMichele’s poster presentation at the 2019 San Antonio Breast Cancer Symposium, Harold J. Burstein, MD, PhD, FASCO, Professor of Medicine at Harvard Medical School and a medical oncologist at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, told The ASCO...
Real-World Use of Palbociclib and Abemaciclib Explored in Two Studies Based on Electronic Health Records Database
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are changing the landscape of the treatment of hormone receptor (HR)-positive/HER2-negative breast cancer. Three CDK4/6 inhibitors are approved by the U.S. Food and Drug Administration—ribociclib, palbociclib, and abemaciclib—as first- or...
ASCO’s Inaugural Breakthrough Global Summit Showcased Evolving Technologies Poised to Revolutionize Cancer Care
Unlike ASCO’s Annual Meeting, symposia, and conferences, which highlight the current scientific advances in specific cancers and how they are improving cancer outcomes for the more than 18.1 million people worldwide diagnosed with cancer each year,1 ASCO Breakthrough: A Global Summit for Oncology...
Peripheral Blood Lymphocytes and T Cells Targeting TP53 Mutations in Patients With Metastatic Solid Tumors
Although TP53 is the most frequently mutated gene across all cancers and encodes the tumor suppressor p53 protein, TP53-targeted therapies have not demonstrated efficacy beyond in vitro models and immunotherapies targeting mutant TP53 are not currently available. A study by Malekzadeh et al...
KEYNOTE-158 Trial: Pembrolizumab Produces Durable Responses in Select Noncolorectal Tumors
As reported in the Journal of Clinical Oncology by Aurelien Marabelle, MD, PhD, of Gustave Roussy, Institut National de la Santé et de la Recherche Médicale, Villejuif, and colleagues, the phase II KEYNOTE-158 trial has shown robust activity of pembrolizumab in patients with noncolorectal high...
FDA Pipeline: Priority Review Granted for Treatment in Lung and Thyroid Cancers
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to a treatment for lung and thyroid cancers with a RET fusion or mutation; gave Breakthrough Therapy designation to a doublet therapy for TP53-mutated myelodysplastic syndromes; and issued an update to their...
Gabapentin and Methadone for Patients Undergoing Treatment of Head and Neck Cancer
With nearly all patients who undergo treatment for cancer of the head and neck experiencing oral mucositis, effective pain control is one of the main goals of physicians and care teams. Looking to provide more effective relief for patients—while also reducing the need for opioid painkillers—a team...
Gabrielle Rocque, MD, MSPH, Followed Three Generations of Doctors Into a Career in Medicine
In 2017, breast cancer expert Gabrielle Rocque, MD, MSPH, received an American Cancer Society Mentored Research Scholar Grant for her work in enhancing shared decision-making for patients with advanced breast cancer. “I come from three generations of physicians,” shared Dr. Rocque. “My father (Dr. ...
Late-Stage Cancer Diagnoses After Massachusetts Health Insurance Reform Law
Advanced-stage cancer diagnoses declined following health insurance expansion in Massachusetts, likely due to increased access to screening and diagnostic services that identified cancers earlier, according to new research published by Sabik et al in the journal Medical Care. The analysis...
Ringing a Bell on the Last Day of Radiation Therapy: Helpful or Harmful?
Some patients with cancer celebrate the end of a course of radiation or chemotherapy by ringing a bell. Indeed, many patients say they love the graduation-like ceremony and the sense of closure it gives them. However, a study published by Williams et al in the International Journal of Radiation...
How Real-World Data Can Help Contextualize New Treatments in Older Patients
Consider a patient who is referred for neoadjuvant therapy for stage IIIA, HER2-positive breast cancer. She is otherwise healthy, with no significant medical history, an Eastern Cooperative Oncology Group performance status of 0, unremarkable baseline labs, and a left-ventricular ejection fraction...
Obstacles to Early Detection of Skin Cancer in Patients Living in Rural Western States
Residents of rural, sparsely populated “frontier counties” in the western United States have a higher incidence of skin cancer and related mortality rates. New research published by Jensen et al in Psychology, Health & Medicine indicated that the biggest obstacle to early detection and...
Study Reports Similar Efficacy but No Less Toxicity With Adjuvant T-DM1 vs Taxane/Trastuzumab in Early Breast Cancer
The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) failed to show improved safety when compared with paclitaxel plus trastuzumab as adjuvant therapy in patients with stage 1 HER2-positive breast cancer. These results of the randomized, phase II ATEMPT trial were presented at the 2019 San ...
2020 GI Cancers Symposium: Cost of Pancreatic Cancer Care Over Time
In a study presented by Picozzi et al at the 2020 Gastrointestinal Cancers Symposium, researchers found that even as drug costs increased over the past decade, total inflation-adjusted pancreatic cancer care expenses declined, as did costs related to quality of life (Abstract 773). Health...
Surgeon General Releases Report Focused on Smoking Cessation
Three decades after the first Surgeon General's report on smoking cessation, the Surgeon General has released a new report that reviews and updates evidence on the importance of quitting smoking. The report finds that more than two-thirds of U.S. adult cigarette smokers report an interest in...
APHINITY Update Supports Benefit of Pertuzumab-Based Triplet in Early HER2-Positive, Node-Positive Breast Cancer
Six-year follow-up of the APHINITY trial found a modest, but not statistically significant, overall survival benefit for the addition of pertuzumab to chemotherapy plus trastuzumab vs chemotherapy/trastuzumab as adjuvant therapy in patients with early HER2-positive breast cancer. The benefit was...
Taking Action Against Cancer: Celebrating 20 Years of World Cancer Day
February 4, 2020, will mark the 20th anniversary of World Cancer Day, an annual event meant to raise cancer awareness and encourage governments, oncology societies, nongovernmental organizations, businesses, and individuals to take action against the global impact of the disease. Formed in...
Largest Single-Year Drop in Cancer Mortality Ever Reported: 2016–2017
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017—the largest single-year drop in cancer mortality ever reported. These findings were reported in “Cancer Statistics, 2020,” the latest edition of the American Cancer Society’s annual report on cancer...
ACCC Project Focuses on Improving Care of Older Adults With Cancer
To prepare the multidisciplinary cancer care team for the growing prevalence of cancer and comorbidities among our nation’s graying population, the Association of Community Cancer Centers (ACCC)—in collaboration with The Gerontological Society of America and the International Society of Geriatric...
TIVO-3: Third- or Fourth-Line Tivozanib vs Sorafenib in Metastatic Renal Cell Carcinoma
As reported in The Lancet Oncology by Brian I. Rini, MD, and colleagues, the phase III TIVO-3 trial has shown a statistically significant increase in progression-free survival with tivozanib vs sorafenib as a third- or fourth-line treatment for advanced renal cell carcinoma. Study Details The...
Practicing Wellness to Reduce Burnout
Numerous wellness strategies are accessible to busy physicians and oncologists, which can be incorporated into their daily routine. Here we discuss such aspects as stress reduction, mindfulness, eating well, sleeping well, and spirituality for the wellness of oncologists. Those who regularly adhere ...
A Deeper Understanding of the Miracle of the Human Body
Despite millennia of anatomic and biomedical search and discovery, there are parts and functions of the human body that remain a mystery. For years, medical students were taught that there are 78 organs in the human body. In February 2017, that number was revised, with the announcement of a new...
A Caregiver’s Tale of Struggle and Lingering Questions
The role of caregiver in the cancer scenario is complicated by various emotions and circumstances beyond the control of the caregiver and the person with cancer. Caregiver stress occurs when there isn’t the time to do all that’s asked or expected of one. Caregiver stress evolves into burnout when...
Seven Haircuts
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Tucatinib Combination Extends Survival in HER2-Positive Metastatic Breast Cancer, Including Patients With Brain Metastases
For patients with progressing HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1), no single regimen is an established standard of care. More than 50% of these patients will develop brain metastasis, and thus far, treatments...
Supportive Care in Oncology Symposium Emphasized Caring for the Whole Patient From Diagnosis to End of Life
The 2019 Supportive Care in Oncology Symposium: Advancing Palliative Research Across the Care Continuum, held this past October in San Francisco, marked the fifth anniversary of its inauguration and its last as a stand-alone ASCO thematic meeting. Since its launch in 2014 as the Palliative Care in...
Cancer No Longer Scares Me
Cancer was a disease I feared until 3 years ago, when I was diagnosed with gastric cancer. After receiving the diagnosis, I knew I didn’t have any time to indulge in fear; I had to take action if I was going to survive. In hindsight, symptoms of the cancer, including some fatigue and indigestion,...
Everolimus/Octreotide Shows Antitumor Activity in Recurrent Meningioma
According to the results from the small phase II CEVOREM trial, a targeted combination of the mTOR inhibitor everolimus and the somatostatin agonist octreotide showed antitumor activity in patients with recurrent meningioma not amenable to any type of surgery or radiotherapy. These findings were...
Radiation Oncologist Felix Y. Feng, MD, Strives for Balance Between Work and Family Life
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Felix Y. Feng, MD, Professor of Radiation Oncology, Urology, and Medicine; George and Judy Marcus Distinguished Professor; Vice Chair of Translational Research in the Department of Radiation...
CancerCare to Provide Support for Patients With Cancer Impacted by the California Wildfires
As many California residents continue to deal with the aftermath of past wildfires and the advent of new ones, CancerCare is now offering a patient assistance program for both emotional and financial support to patients with cancer affected by the California fires. As a leading national nonprofit...
Optimizing Metabolic Discoveries
Obesity is a leading cause of cancer, and researchers are working to learn more about the biology behind the body’s metabolism and the promotion of cancer growth. “While we know that physical activity and a balanced diet are generally healthy, we don’t yet have the data to make personalized...
Motivating Yourself for Exercise Goals in the New Year
The day after Christmas, I walked into the exercise studio and spent the next hour jogging, rowing, and doing exactly what that morning’s coach instructed the 20 or so participants of the class to do next. The hour passed quickly, and I had little or no time to think about anything other than the...
ASCO Releases Major Update to Payment Reform Model
ASCO released a major update to its Patient-Centered Oncology Payment (PCOP) model, an alternative payment model designed to support transformation in cancer care delivery and reimbursement, while ensuring that patients with cancer have access to high-quality, high-value care. PCOP addresses an...
ASCO Announces Newly Elected Leadership
ASCO has elected Everett E. Vokes, MD, FASCO, a long-time member and volunteer, to serve as its President for the term beginning in June 2021. Dr. Vokes will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2020. Six members were also elected to open positions on...
FDA’s Pilot Project Patient Voice Website and Workshop With ASCO
Project Patient Voice (PPV) is a program that will gather and make available online, patient-reported outcomes from cancer clinical trials. Launched by the U.S. Food and Drug Administration (FDA)’s Oncology Center of Excellence (OCE), it is the first program of its kind to communicate...
Value-Based and Patient-Centered Cancer Care: Looking at Closing Gaps in Perspectives of Value
Value-based care in oncology—a concept that emphasizes quality over quantity—has evolved over the past 2 decades to become a guiding principle of both public and private payers. The concept was part of the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008; informed elements of...
Two New Grants to Support Transformative Cancer Research
Two grants for research that could transform cancer therapies have been funded through an innovative partnership between the American Association for Cancer Research (AACR) and MPM Capital through its management of the UBS Oncology Impact Fund. This unique grant program allows investigators to...
2020 GI Cancers Symposium: Young Adults With Colorectal Cancer Living in Areas of Low Income, Education Likely to Have Worse Survival Outcomes
A retrospective analysis of 26,768 young adults with colorectal cancer aged 40 and under found that those who live in areas with lower income (a median income of less than $38,000) and less education (under 79% high school graduation rate), as well as those who live in urban areas, had worse...
Expert Point of View: Hope S. Rugo, MD, FASCO, and Laura J. Esserman, MD, MBA, FASCO
Hope S. Rugo, MD, FASCO, Professor of Medicine, Director of Breast Oncology and Clinical Trials at the University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, said the residual cancer burden index is being increasingly used in medical oncology. “The...
Expert Point of View: Debra Patt, MD, MPH, MBA
Debra Patt, MD, MPH, MBA, Executive Vice President of Policy and Strategy for Texas Oncology and Clinical Professor at Dell Medical School at the University of Texas at Austin, commented that the 10-year results of NSABP B-42 show “a substantial improvement” in disease-free survival, with an...
Extended Letrozole Boosts Disease-Free Survival in 10-Year Update of NSABP B-42 Trial
“In the 10-year analysis of the NSABP B-42 trial, the effect of extended treatment with 5 years of letrozole on disease-free survival persisted and reached statistical significance. There was no significant improvement in overall survival with letrozole, but letrozole continued to provide a...
Brentuximab Vedotin Plus Nivolumab in Hodgkin Lymphoma
The combination of brentuximab vedotin and nivolumab is making headway as first-line therapy for older adults with Hodgkin lymphoma and as salvage therapy for adults with relapsed or refractory classic Hodgkin lymphoma, according to separate studies presented at the 2019 Annual Meeting &...
Mixed Results With Weekly Nab-paclitaxel, Denosumab in Primary Breast Cancer
A weekly schedule of nab-paclitaxel as part of neoadjuvant chemotherapy significantly improved pathologic complete response compared with nab-paclitaxel given 2 weeks out of every 3 weeks (2/3) in patients with primary breast cancer, with a greater magnitude of benefit in patients with...
Cancer Incidence in World Trade Center Responders to the September 11 Attacks
A study published by Shapiro et al in JNCI Cancer Spectrum showed that responders to the World Trade Center site after the attacks on September 11, 2001, have statistically significant elevations in cancer incidence for all cancer sites combined, and for prostate and thyroid cancer and leukemia....
Relapse and Outcomes in Men Receiving Adjuvant Bleomycin/Etoposide/Cisplatin for Clinical Stage I Nonseminoma
In a study reported in the Journal of Clinical Oncology, Fischer et al found different patterns of relapse and associated outcomes among men with relapse after treatment with adjuvant bleomycin/etoposide/cisplatin for clinical stage I nonseminoma. The study included data on 51 patients from 18...
